ArticleEpigenetics
Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence.
Article in Epigenetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Discovery of 5-(Substituted Phenyl)-2-aryl Benzimidazole Derivatives as SIRT1 Activators: Their Design,Current medicinal chemistry · 2026Article
- Pharmacological Investigation of a Novel Resveratrol-like SIRT1 Activator Endowed with a Cardioprotective Profile.Molecules (Basel, Switzerland) · 2025Article
- Oxidative-Inflammatory Crosstalk and Multi-Target Natural Agents: Decoding Diabetic Vascular Complications.Current issues in molecular biology · 2025Review
- Epigenetic regulation of histone 3 acetylation and p53 by SIRT1 overexpression in an experimental model of alveolar epithelium damage.Journal of biosciences · 2025Article
- Cellular Senescence and Inflammaging in the Bone: Pathways, Genetics, Anti-Aging Strategies and Interventions.International journal of molecular sciences · 2024Review
- Article
- Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.Theranostics · 2024Review
- SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism.Journal of translational medicine · 2023Article
- NADAntioxidants (Basel, Switzerland) · 2023Review
- Molecular Docking Study of Phytosterols inJournal of experimental pharmacology · 2023Article
- Resveratrol-like Compounds as SIRT1 Activators.International journal of molecular sciences · 2022Article
- SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders.Aging clinical and experimental research · 2022Review
- SIRT1 pharmacological activation rescues vascular dysfunction and prevents thrombosis in MTHFR deficiency.Cellular and molecular life sciences : CMLS · 2022Article
- Multi-Systemic Alterations by Chronic Exposure to a Low Dose of Bisphenol A in Drinking Water: Effects on Inflammation and NADInternational journal of molecular sciences · 2021Article
- Exploring the recent molecular targets for diabetes and associated complications.Molecular biology reports · 2021Review
- Sirtuin 1 in Endothelial Dysfunction and Cardiovascular Aging.Frontiers in physiology · 2021Review
- Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism.Cells · 2020Review
Corrections and comments
- Erratum issuedCorrection.2025
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SIRT1, a NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.